## FORM 4

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

#### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Ty	pe Response	s)															
1. Name and Address of Reporting Person* SALZMAN BARRY M				2. Issuer Name and Ticker or Trading Symbol Checkpoint Therapeutics, Inc. [CKPT]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner					
(Last) (First) (Middle) 2 GANSEVOORT STREET, 9TH FLOOR				3. Date of Earliest Transaction (Month/Day/Year) 06/10/2021									er (give title belo		Other (specify b	elow)	
(Street)				4. If Amendment, Date Original Filed(Month/Day/Year)							/Day/Year)	6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting Person					
NEW YO	ORK, NY	10014												ou by More than	One Reporting	CISON	
(City	)	(State)	(Zip)		Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned												
(Instr. 3)		2. Transaction Date (Month/Day/Year)			ate, if	(Instr. 8)		(A) or Dispose		Disposed	of (D) Beneficia Reported		nt of Securities ally Owned Following Transaction(s)		6. Ownership Form:	Beneficial	
				(Mon	onth/Day/Year	Year)		ode	V	Amour	(A) or (D)	Price		o. (I		` /	Ownership (Instr. 4)
COMMON STOCK 06/10		06/10/2021				A			16,50 (1)	2 A	\$ 0	128,782 (2)			D		
			Table II - I					ti quired	contai the fo	ined ir rm dis posed o	n this for splays a of, or Ben	m are curre	e not requently valid	OMB cont	spond unle rol numbe	ss	1474 (9-02)
1. Title of	l <sub>o</sub>	3. Transaction	,								tible secu	<del>–</del>		0 D.: f	0. November	of 10.	11 . N
Derivative Security	Conversion or Exercise Price of Derivative Security	Date (Month/Day/Yo	Execution Dat	te, if	, if Transaction Code ear) (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)			Am Und Sec	Title and ount of derlying urities tr. 3 and	Derivative Security (Instr. 5)	9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s (Instr. 4)	Ownersh Form of Derivati Security Direct (I or Indire	Beneficial Ownership (Instr. 4)
								-	Date Exerci		Expiration Date	n Titl	Amount or Number of				

#### **Reporting Owners**

	Relationships					
Reporting Owner Name / Address	Director	10% Owner	Officer	Other		
SALZMAN BARRY M 2 GANSEVOORT STREET, 9TH FLOOR NEW YORK, NY 10014	X					

# **Signatures**

/s/ James F. Oliviero, Attorney-in-Fact	06/11/2021
**Signature of Reporting Person	Date

### **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The 16,502 shares of restricted Common Stock will vest on June 10, 2024, subject to Mr. Salzman's continued service on the board on such
- (2) Includes restricted shares of Common Stock which vest over various time periods, subject to Mr. Salzman's continued service on the board.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.